Todd Creech, MBA


Todd has spent the last nine years as a healthcare CFO, helping build several successful companies to profitable exits. He joined HealthQuest in 2016 to bring his operations and financial experiences to innovative companies that are primed for growth with the right plan and execution. He currently serves as board member of HealthQuest portfolio company Alcresta, BioIQ and Etairos and an observer for HealthChannels, Springbuk, InMediata, Avedro and Venus Concept.

Previously, he was the CFO for Femasys, a medtech company developing and selling devices targeted at women’s health issues. Prior to that, he was CFO and Treasurer of ZS Pharma (IPO in 2014 and sold to AstraZeneca in 2015; a 30x increase in valuation from when he joined in 2013).  Todd was the CFO and led business development activities for Sarcode which developed lifitigrast, the first dry-eye pharmaceutical to be approved (2016) for both signs and symptoms of dry eye (sold to Shire in 2013).  He was also the CFO of Sirion Therapeutics, an ophthalmic company that successfully developed and received approval for two products (Durezol and Virgan) and sold to Alcon and Bausch and Lomb in 2010. During his CFO tenure he has raised more than $500M in equity and debt, helping to build operations and companies that generated over $3.5B in exits.

Earlier in his career, Todd did healthcare venture investing for Quintiles and worked with SRI International. He has also co-founded two companies; a spectroscopy platform spinout of Duke University (Centice) and a specialty pharmaceutical company (TLC Pharma).

Todd holds bachelor's degrees in Finance and Accounting from Miami (Ohio) University where he was also a scholarship baseball player, and an MBA from Duke University. He is an Executive-in-Residence for Moffitt Cancer Center and sits on the Healthcare Advisory Board for Duke’s Fuqua School of Business. He is also on the boards of Southeast Bio and the Southeast Medical Device Association. He and his wife live with their two sons.